The intramolecular Schmidt reaction of azides with tertiary alcohols: Synthesis of 5-(α-naphthyl)- and 5-(β-naphthyl)indolizidines as potential dopamine analogs and non-opiate antinociceptive agents

Tetrahedron

Volumn 52, Issue 37, 1996, Pages 12039-12048

  Pearson, William H ^a   Gallagher, Brian M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,4,5',6,6',7,12B OCTAHYDRO 1',3' DIMETHYL 2H SPIRO[BENZO[B]FURO[2,3 A]QUINOLIZINE 2,4' PYRIMIDINE] 2' ONE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; DOPAMINE 2 RECEPTOR; INDOLIZIDINE DERIVATIVE; PRAZOSIN; SPIPERONE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CHO CELL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; RAT; REACTION ANALYSIS;

ANIMALIA;

EID: 0030576891     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/0040-4020(96)00723-5     Document Type: Article

References (36)

1. (1) Carlsson, A.; Lindqvist, M.; Magnusson, T.; Waldeck, B. Science 1958, 127, 471.
2. (2) Calne, D. B.; Larsen, T. A. In Dopamine Receptors, ACS Symposium Series 224; C. Kaiser and J. W. Kebabian, Ed.; American Chemical Society: Washington, 1983; pp 147-153.
3. (3) Ram, V. J.; Neumeyer, J. L. J. Org. Chem 1981, 46, 2830-2831.
4. (4) Bruderlein, F. T.; Humber, L. G.; Voith, K. J. Med. Chem. 1975, 18, 185-188.
5. (5) Humber, L. G.; Bruderlein, F. T.; Philipp, A. H.; Götz, M. J. Med. Chem. 1979, 22, 761-767.
6. (6) Philipp, A. H.; Humber, L. G.; Voith, K. J. Med. Chem. 1979, 22, 768-773.
7. (7) Humber, L. G.; Philipp, A. H.; Voith, K.; Pugsley, T.; Lippmann, W.; Ahmed, F. R.; Przybylska, M. J. Med. Chem. 1979, 22, 899-901.
8. (8) Livingstone, C. D.; Strange, P. G.; Naylor, L. H. Biochem. J. 1992, 287, 277-282.
9. (9) Mansour, A.; Meng, F.; Meador-Woodruff, J. H.; Taylor, L. P.; Civelli, O.; Akil, H. European Journal of Pharmacology-Molecular Pharmacology Section 1992, 227, 205-214.
10. (10) Seiler, M. P.; Bolsterli, J. J.; Floersheim, P.; Hagenbach, A.; Markstein, R.; Pfaffli, P.; Widmer, A.; Wurthrich, H. In Perspectives in Medicinal Chemistry; B. Testa; E. Kyburz; F. Walter and R. Giger, Ed.; VCH: New York, 1993; pp 221-237.
11. (11) Nichols, D. E. In Dopamine Receptors, ACS Symposium Series 224; C. Kaiser and J. W. Kebabian, Ed.; American Chemical Society: Washington, D. C., 1983; pp 201-221.
12. (12) Kaiser, C. In Dopamine Receptors, ACS Symposium Series 224; C. Kaiser and J. W. Kebabian, Ed.; American Chemical Society: Washington, D. C., 1983; pp 223-246.
13. (13) Kaiser, C. In Dopamine Receptor Agonists; G. Poste and S. T. Crooke, Ed.; Plenum Press: New York, 1984; pp 87-137.
14. (14) Cannon, J. G. Prog. Drug Res. 1985, 29, 303-414.
15. (15) Högberg, T.; Ramsby, S.; Ogren, S.-o.; Norinder, U. Acta. Pharm. Suec. 1987, 24, 289-328.
16. (16) Petcher, T. J. In Basic and Clinical Aspects of Neuroscience; E. Flückiger; E. E. Müller and M. O. Thorner, Ed.; Springer-Verlag: New York, 1989; Vol. 3; pp 47-55.
17. (17) Högberg and coworkers have discussed the naphthalene-like receptor binding site which allows for binding of both butaclamol (3) and isobutaclamol (4). See ref. 15 and references cited therein.
18. (18) Hill and Lafferty have reported the synthesis of 4-substituted-1-(β-naphthylmethyl)piperazines that have anti-Parkinsonism activity. See: Hill, H. F.; Lafferty, J. J., U. S. Patent 3,919,230, 1975.
19. (19) Carson, J. R.; Carmosin, R. J.; Vaught, J. L.; Gardocki, J. F.; Costanzo, M. J.; Raffa, R. B.; Almond, H. R., Jr. J. Med. Chem. 1992, 35, 2855-2863.
20. (20) Pearson, W. H.; Schkeryantz, J. M. Tetrahedron Lett. 1992, 33, 5291-5294.
21. (21) Pearson, W. H.; Walavalkar, R.; Schkeryantz, J. M.; Fang, W.-k.; Blickensdorf, J. D. J. Am. Chem. Soc. 1993, 115, 10183-10194.
22. (22) Pearson, W. H.; Fang, W.-k. J. Org. Chem 1995, 60, 4960-4961.
23. (23) For leading references for Aubé's work on Schmidt reactions of azides with carbonyl compounds, see: (a) Aubé, J.; Milligan, G. L. J. Am. Chem. Soc. 1991, 113, 8965-8966.
24. (b) Milligan, G. L.; Mossman, C. J.; Aubé, J. J. Am. Chem. Soc. 1995, 117, 10449-10459.
25. (24) Maryanoff, B. E.; McComsey, D. F.; Leo, G. C.; Almond, H. R., Jr. J. Org. Chem. 1992, 57, 1190-1195.
26. (25) Bohlmann, F. Chem. Ber. 1958, 91, 2157-2167.
27. (26) Bohlmann, F.; Schumann, D.; Arndt, C. Tetrahedron Lett. 1965, 2705-2711.
28. (27) Garraffo, H. M.; Caceres, J.; Daly, J. W.; Spande, T. F.; Andriamaharavo, N. R.; Andriantsiferana, M. J. Nat. Prod. 1993, 56, 1016-1038.
29. (28) Imamoto, T.; Takiyama, N.; Nakamura, K.; Hatajima, T.; Kamiya, Y. J. Am. Chem. Soc. 1989, 111, 4392-4398.
30. (29) Molecular modeling and comparison overlays were carried out using PCMODEL version 5.0-PPC.
31. (30) Pugsley, T. A.; Davis, M. D.; Akunne, H. C.; Mackenzie, R. G.; Shih, Y. H. ;. D., G.; Wikstrom, H.; Whetzel, S. Z.; Georgic, L. M.; Cooke, L. W.; Demattos, S. B.; Corbin, A. E.; Glase, S. A.; Wise, L. D.; Dijkstra, D.; Heffner, T. G. Pharmacol. Exp. Therap. 1995, 275, 1355-1366.
32. (31) Morrow, A. L.; Creese, I. Mol. Pharmacol. 1986, 29, 321-330.
33. (32) Pettibone, D. J.; Flagg, S. D.; Totaro, J. A.; Clineschmidt, B. V.; Huff, J. R.; Young, S. D.; Chen, R. Life Sci. 1989, 44, 459-467.
34. (33) Watson, S. C.; Eastham, J. F. J. Organometal. Chem. 1967, 9, 165-168.
35. (34) Hindered rotation about the bond between the indolizidine ring and the aromatic ring led to a complex NMR spectrum at room temperature, necessitating data aquisition at temperatures above the coalescence point.
36. (35) Prepared in 98% yield from 6-bromo-2-naphthol by treatment with NaH (1.1 equiv., THF, 0 °C, 1h) followed by MeI (2.0 equiv., 0 °C to room temperature). For a recent synthesis, see: Bernas, B. R.; Hossain, M. M. Eur. Polym. J. 1993, 29, 657-659.